L-carnitine as an adjunct therapy to percutaneous coronary intervention for Non-ST elevation myocardial infarction

To evaluate the effects of L-carnitine as an adjunct therapy to percutanenous coronary intervention (PCI) for non-ST elevation acute coronary syndrome (NSTEMI). Ninety-six consecutive patients with NSTEMI were randomized into treatment group (L-carnitine 5 g IV bolus followed by 10 g/day IV infusion for 3 days), and control group. All patients also underwent PCI within 24 h from the onset of chest pain. The peak values of creatine kinase-MB and troponin-I before and after PCI were observed. In the treatment group, the peak values of creatine kinase-MB were significantly lower than the control group at 12 h and 24 h after PCI (P < 0.01). The peak values of troponin-I in the treatment group were also lower than the control group at 8 h after PCI (P < 0.01). Multivariate regression analysis showed that L-carnitine therapy was an independent predictor for the reduction of creatine kinase-MB (r=0.596, P < 0.001) or troponin-I (r=0.633, P < 0.001). L-carnitine adjunct therapy appears to be associated with a reduced level of cardiac markers in patients with NSTEMI. These results support a larger clinical trial to investigate the effect of L-carnitine on cardiac events following PCI.